Gilead Sciences' stock has increased significantly due to positive news in its pipeline and better-than-expected performance, which are strong drivers for the stock price. However, the slower growth in oncology and the already realized momentum suggest that while the short-term impact is positive, investors should be cautious about future growth potential.